In recent years, the pharmaceutical and biotech industries have undergone transformative changes, significantly impacting their research-based approaches. This course explores these momentous developments, including the emergence of digital-based health technologies, the integration of real-world experience (RWE) and real-world data (RWD) in the drug approval process, and the widespread dissemination of evolving medical information to a diverse audience.

While these advancements offer tremendous opportunities, they also come with new regulatory challenges. One critical concern involves the promotion practices and activities within the industry, raising compliance issues. Government authorities, including the FDA, state and federal bodies, and agencies such as the Office of Inspector General of the Department of Health and Human Services (OIG), the Department of Justice (DOJ), and state attorneys general, have become increasingly vigilant in investigating off-label promotion.

These investigations have resulted in substantial fines and the imposition of rigorous Corporate Integrity Agreements. To navigate these intricate compliance and regulatory matters successfully, this CLE course delivers a comprehensive overview. Participants will explore the methods and strategies being developed and implemented to establish effective policies and procedures, ensuring compliant promotion and responsible dissemination of scientific information to both medical professionals and the general public.